The antiangiogenic agents TNP-470 and 2-methoxyestradiol inhibit the growth of angiosarcoma in mice

被引：39
作者：
Arbiser, JL
Panigrathy, D
Klauber, N
Rupnick, M
Flynn, E
Udagawa, T
D'Amato, RJ
机构：
[1] Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA
[2] Harvard Univ, Childrens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 1999年 / 40卷 / 06期
关键词：
D O I：
10.1016/S0190-9622(99)70080-0
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
Background: Endothelial malignancies, such as angiosarcoma and hemangioendothelioma, are often resistant to chemotherapy and surgery, and may result in death. Improved means of therapy are needed for these disorders. Objective: We wanted to determine whether angiosarcoma can be treated with angiogenesis inhibitors in mice. Methods: Mice were inoculated with a cell line that gives rise to angiosarcoma and were treated with the angiogenesis inhibitors 2-methoxyestradiol and TNP-470. Response to therapy was monitored by measurement of tumors. Results: TNP-470 caused an 84% reduction in tumor size, and 2-methoxyestradiol caused a 68% reduction in tumor size. Conclusion: Angiogenesis inhibitors are highly effective in treatment of angiosarcoma in mice. Clinical trials of these agents in humans with angiosarcoma and hemangioendothelioma are warranted.
引用
收藏
页码：925 / 929
页数：5
相关论文
共 20 条
[1]   Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways [J].
Arbiser, JL ;
Moses, MA ;
Fernandez, CA ;
Ghiso, N ;
Cao, YH ;
Klauber, N ;
Frank, D ;
Brownlee, M ;
Flynn, E ;
Parangi, S ;
Byers, HR ;
Folkman, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (03) :861-866
[2]  
BLEI F, 1996, J AM ACAD DERMATOL, V34, P337
[3]   Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance [J].
Boehm, T ;
Folkman, J ;
Browder, T ;
OReilly, MS .
NATURE, 1997, 390 (6658) :404-407
[4]   2-METHOXYESTRADIOL, AN ENDOGENOUS MAMMALIAN METABOLITE, INHIBITS TUBULIN POLYMERIZATION BY INTERACTING AT THE COLCHICINE SITE [J].
DAMATO, RJ ;
LIN, CM ;
FLYNN, E ;
FOLKMAN, J ;
HAMEL, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :3964-3968
[5]   Fumagillin analog in the treatment of Kaposi's sarcoma: A phase I AIDS Clinical Trial Group Study [J].
Dezube, BJ ;
Von Roenn, JH ;
Holden-Wiltse, J ;
Cheung, TW ;
Remick, SC ;
Cooley, TP ;
Moore, J ;
Sommadossi, JP ;
Shriver, SL ;
Suckow, CW ;
Gill, PS .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1444-1449
[6]  
ENJOLRAS O, 1990, PEDIATRICS, V85, P491
[7]   INTERFERON ALFA-2A THERAPY FOR LIFE-THREATENING HEMANGIOMAS OF INFANCY [J].
EZEKOWITZ, RAB ;
MULLIKEN, JB ;
FOLKMAN, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (22) :1456-1463
[8]  
FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0
[9]  
GOLDMAN R, 1979, J NATL CANCER I, V63, P1009
[10]   SYNTHETIC ANALOGS OF FUMAGILLIN THAT INHIBIT ANGIOGENESIS AND SUPPRESS TUMOR-GROWTH [J].
INGBER, D ;
FUJITA, T ;
KISHIMOTO, S ;
SUDO, K ;
KANAMARU, T ;
BREM, H ;
FOLKMAN, J .
NATURE, 1990, 348 (6301) :555-557
12